Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
404-02-004 ISMRM Abstract

In vivo biochemical subtyping of multiple sclerosis lesions using 7T 3D CRT free induction decay MRSI

Primary: Neuro - Multiple Sclerosis
Secondary: Contrast Mechanisms - Spectroscopy
404-02-004 · Altered Metabolism Across Healthy Aging and Neurological Disorders · Tuesday, 12 May, 8:20 AM–10:10 AM · Ballroom East
Keywords: Multiple Sclerosis Neuroinflammation 3D magnetic resonance spectroscopic imaging Metabolic profiling and Fingerprinting Lesion Phenotyping
Accepted
Rebeka Rumbak 1,2, Anita Kloss-Brandstätter3, Fabian Niess1, Bernhard Strasser1, Lukas Hingerl1, Stanislav Motyka1,4, Thomas Berger1,2, Guenther Grabner5, Paulus Rommer1,2, Wolfgang Bogner1,4, Assunta Dal-Bianco1,2, Eva Niess1
1Medical University of Vienna, Vienna, Austria
2Department of Neurology, Medical University of Vienna, Vienna, Austria
3Department of Engineering & IT, Carinthia University of Applied Sciences, Villach, Austria, Austria
4Christian Doppler Laboratory for MR Imaging Biomarkers (BIOMAK), Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
5Department of Medical Engineering, Carinthia University of Applied Sciences, Klagenfurt, Austria
Presenting Author: Rebeka Rumbak

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8(3):a028936. doi:10.1101/cshperspect.a028936 [doi]
2. Brune S, Høgestøl EA, Cengija V, et al. LesionQuant for assessment of MRI in multiple sclerosis: a promising supplement to the visual scan inspection. Front Neurol. 2020;11:546744. doi:10.3389/fneur.2020.546744 [doi]
3. Kolb H, Al-Louzi O, Beck ES, Sati P, Absinta M, Reich DS. From pathology to MRI and back: clinically relevant biomarkers of multiple sclerosis lesions. Neuroimage Clin. 2022;36:103194. doi:10.1016/j.nicl.2022.103194 [doi]
4. Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. 2019;142(7):1858-1875. doi:10.1093/brain/awz144 [doi]
5. Hingerl L, Strasser B, Moser P, et al. Clinical high-resolution 3D-MR spectroscopic imaging of the human brain at 7T. Invest Radiol. 2020;55(4):239-248. doi:10.1097/RLI.0000000000000626 [doi]
6. Moser P, Bogner W, Hingerl L, et al. Non-Cartesian GRAPPA and coil combination using interleaved calibration data: application to concentric-ring MRSI of the human brain at 7T. Magn Reson Med. 2019;82(5):1587-1603. doi:10.1002/mrm.27822 [doi]
7. Niess E, Dal-Bianco A, Strasser B, et al. Topographical mapping of metabolic abnormalities in multiple sclerosis using rapid echo-less 3D-MR spectroscopic imaging at 7T. Neuroimage. 2025;308:121043. doi:10.1016/j.neuroimage.2025.121043 [doi]
8. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622-1636. doi:10.1016/S0140-6736(18)30481-1 [doi]
9. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053 [doi]
10. Grabner G, Dal-Bianco A, Schernthaner M, Vass K, Lassmann H, Trattnig S. Analysis of multiple sclerosis lesions using a fusion of 3.0T FLAIR and 7.0T SWI phase: FLAIR SWI. J Magn Reson Imaging. 2011;33(3):543-549. doi:10.1002/jmri.22452 [doi]
11. Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15(3):292-303. doi:10.1016/S1474-4422(15)00393-2 [doi]
12. Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Long-term evolution of multiple sclerosis iron rim lesions in 7T MRI. Brain. 2021;144(3):833-847. doi:10.1093/brain/awaa436 [doi]
13. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672-679. doi:10.1002/mrm.1910300604 [doi]
14. Lin A, Andronesi O, Bogner W, et al. Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): experts’ consensus recommendations. NMR Biomed. 2021;34(5):e4484. doi:10.1002/nbm.4484 [doi]
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis. Neurology. 1983;33(11):1444-1444. doi:10.1212/WNL.33.11.1444 [doi]
16. Kalinowski A, Cutter G, Bozinov N, et al. The timed 25-foot walk in a large cohort of multiple sclerosis patients. Mult Scler. 2022;28(2):289-299. doi:10.1177/13524585211017013 [doi]
17. Koch MW, Repovic P, Mostert J, et al. The nine hole peg test as an outcome measure in progressive MS trials. Mult Scler Relat Disord. 2023;69:104433. doi:10.1016/j.msard.2022.104433 [doi]
18. Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721-733. doi:10.1177/1352458517690821 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/404-02-004